Gilead Sciences: Hepatitis C trials

The registry lists 130 Hepatitis C studies with Gilead Sciences as lead sponsor. 0 are open to participants now and 98 have results posted.

Phase 1 14Phase 2 60Phase 3 44Phase 4 1No phase 13(a study in two phases counts in both)

Studies

Page 2 of 2. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Sovaldi-based Regimens in Patients in Mexico With Chronic Hepatitis C Virus Infection in Clinical PracticeCompletedNCT02783976
• Safety and Efficacy of Sofosbuvir-based Regimens in Clinical Practice for the Treatment of Chronic Hepatitis C Virus Infection in IndiaCompletedNCT02592057
• Use-Results Surveillance Study of Harvoni® in Japanese Patients With Chronic Genotype 1 Hepatitis C Virus InfectionCompletedNCT02591277
• Use-Results Surveillance Study of Sovaldi® Plus Rebetol® in Japanese Patients With Chronic Genotype 2 Hepatitis C Virus InfectionCompletedNCT02562742
• Use-Results Surveillance Study of Sovaldi® Plus Copegus® in Japanese Patients With Chronic Genotype 2 Hepatitis C Virus InfectionCompletedNCT02537379
• A Registry for Adolescent and Pediatric Participants Who Received a Gilead Hepatitis C Virus Direct Acting Antiviral (DAA) in Gilead-Sponsored Chronic Hepatitis C Infection TrialsTerminatedNCT02510300
• A Phase 1 Study to Evaluate the Pharmacokinetics of GS-5816 in Subjects With Normal Hepatic Function and Moderate or Severe Hepatic ImpairmentCompletedNCT01817985Phase 1
• Expanded Access Program of Sofosbuvir With Ribavirin and With or Without Pegylated Interferon in Aggressive Post-transplant Hepatitis CApproved for marketingNCT01779518
• Observational Study on Prevalence of Host and Viral Genotypes in Chronic Hepatitis B and Hepatitis C Patients in IndiaCompletedNCT01772121
• A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis CCompletedNCT01591668Phase 1
• Open-Label Hepatic Impairment StudyCompletedNCT01497327Phase 1
• A Gilead Sequence Registry of Subjects Who Did Not Achieve Sustained Virologic ResponseCompletedNCT01457768
• Gilead Sustained Virologic Response (SVR) RegistryCompletedNCT01457755
• GS-5885, GS-9451, Tegobuvir and Ribovirin in Treatment-Experienced Subjects With Chronic Genotype 1a Or 1b Hepatitis C Virus (HCV) InfectionCompletedNCT01435226Phase 2
• Safety Study of Regimens of Sofosbuvir, GS-0938, and Ribavirin in Patients With Chronic Hepatitis C InfectionCompletedNCT01435044Phase 2
• GS-5885, GS-9451, Tegobuvir and Ribavirin (RBV) in Interferon Ineligible or Intolerant Subjects With Chronic Genotype 1a or 1b Hepatitis C Virus (HCV) InfectionCompletedNCT01434498Phase 2
• Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GS-9669 in Subjects With Chronic Hepatitis C Virus InfectionCompletedNCT01431898Phase 1
• GS-5885, GS-9451 With Peginterferon Alfa 2a (PEG) and Ribavirin in Treatment-Naïve Subjects With Chronic Genotype 1 Hep C Virus Infection and IL28B CC GenotypeTerminatedNCT01384383Phase 2
• Oral Antivirals (GS-5885, Tegobuvir, and/or GS-9451) With Peginterferon Alfa 2a and Ribavirin in Treatment Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus InfectionCompletedNCT01371578Phase 2
• GS-5885 Alone or in Combination With GS-9451 With Peginterferon Alfa 2a and Ribavirin in Treatment Chronic Genotype 1 Hepatitis C VirusCompletedNCT01356160Phase 2
• GS 5885 Administered Concomitantly With GS-9451, Tegobuvir and Ribavirin (RBV) in Chronic Genotype 1 Hepatitis C Virus (HCV) InfectionCompletedNCT01353248Phase 2
• A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GS-6620 in Treatment Naïve Subjects With Chronic Hepatitis C Virus InfectionCompletedNCT01316237Phase 1
• A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis CCompletedNCT01271790Phase 2
• A Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-9256, Pegasys® and Copegus® in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis CCompletedNCT01225380Phase 2
• A Multiple Ascending Dose Study of GS 5885 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis CCompletedNCT01193478Phase 1
• Efficacy and Safety Study of GS-9256 and GS-9190 Alone and in Combination With Ribavirin for 28 Days in Patients With Chronic Hepatitis C Virus InfectionCompletedNCT01072695Phase 2
• Efficacy and Safety Study of GS-9450 Treatment for 6 Months in Patients With Chronic Hepatitis C Virus InfectionTerminatedNCT00874796Phase 2
• Safety, Tolerability, and Antiviral Activity of 24 or 48 Weeks of GS-9190 in Combination With Peginterferon Alfa 2a and Ribavirin for the Treatment of Genotype-1 Chronic HCV InfectionCompletedNCT00743795Phase 2
• Evaluation of the Safety, Tolerability, Pharmacokinetics, and Activity of GS-9450 in Subjects With Chronic HCVCompletedNCT00725803Phase 2
• Adaptive Phase I HCV Study With Nucleoside Analogue, in Combination With Interferon and RibavirinCompletedNCT00382798Phase 1/2